Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Randomised, Phase II Study Evaluating the Efficacy and Safety of Addition of Continuous Multiple Line Bevacizumab Treatment to Lomustine in Second (2nd)-Line Followed by Standard of Care (SOC) in Third (3rd)-Line and Beyond Compared to Addition of Placebo, Following First Progression of Disease (PD1) in Patients With Glioblastoma (GBM) After First (1st)-Line Treatment With Radiotherapy, Temozolomide and Bevacizumab
Brief Summary: This multicenter, double-blind, placebo-controlled, randomized study will evaluate the efficacy and safety of the addition of bevacizumab treatment to lomustine (in 2nd-line \[2L\] treatment) and SOC (in 3rd-line \[3L\] and subsequent lines of treatment) following first-line disease progression (PD1) in participants with newly diagnosed glioblastoma. All enrolled participants will receive 1L treatment with radiotherapy, temozolomide, and bevacizumab. At PD1, eligible participants will be randomized (1:1) to receive 2L treatment with either bevacizumab plus lomustine or placebo plus lomustine. After second-line disease progression (PD2), participants will receive 3L treatment and will continue blinded bevacizumab or placebo with the addition of an SOC agent. Following third-line disease progression (PD3), participants will receive subsequent lines of treatment and will either continue blinded bevacizumab or placebo (at the discretion of the investigator), or switch to open-label bevacizumab (at the choice of the participant).


Options:
A: Arm Label: Carbon Ion Radiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Carbon Ion Radiotherapy | Arm Label: Standard Treatment: Fractionated Stereotacitc Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Fractionated Stereotactic Radiotherapy (FSRT) | Intervention Type: RADIATION; Name: Carbon Ion Radiotherapy; Assigned to Arm(s): Carbon Ion Radiotherapy | Intervention Type: RADIATION; Name: Fractionated Stereotactic Radiotherapy (FSRT); Assigned to Arm(s): Standard Treatment: Fractionated Stereotacitc Radiotherapy
B: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Drug: dasatinib | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Biological: bevacizumab, Other: placebo | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: dasatinib; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alkylating Agents | Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Disulfiram, Dietary Supplement: Copper, Drug: Alkylating Agents | Intervention Type: DRUG; Name: Disulfiram; Assigned to Arm(s): Experimental | Intervention Type: DIETARY_SUPPLEMENT; Name: Copper; Assigned to Arm(s): Experimental | Intervention Type: DRUG; Name: Alkylating Agents; Assigned to Arm(s): Control, Experimental
D: Arm Label: First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Lomustine, Radiation: Radiotherapy, Drug: Temozolomide, Drug: SOC Agent | Arm Label: First-Line Bevacizumab followed by Placebo + Lomustine/SOC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Lomustine, Drug: Placebo, Radiation: Radiotherapy, Drug: Temozolomide, Drug: SOC Agent | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC, First-Line Bevacizumab followed by Placebo + Lomustine/SOC | Intervention Type: DRUG; Name: Lomustine; Assigned to Arm(s): First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC, First-Line Bevacizumab followed by Placebo + Lomustine/SOC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): First-Line Bevacizumab followed by Placebo + Lomustine/SOC | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC, First-Line Bevacizumab followed by Placebo + Lomustine/SOC | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC, First-Line Bevacizumab followed by Placebo + Lomustine/SOC | Intervention Type: DRUG; Name: SOC Agent; Assigned to Arm(s): First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC, First-Line Bevacizumab followed by Placebo + Lomustine/SOC

Answer: D